US Bancorp DE Sells 11,043 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

US Bancorp DE decreased its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 42.4% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,032 shares of the company’s stock after selling 11,043 shares during the quarter. US Bancorp DE’s holdings in Elanco Animal Health were worth $221,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Canada Pension Plan Investment Board bought a new stake in Elanco Animal Health in the second quarter valued at about $55,599,000. Magnetar Financial LLC grew its stake in shares of Elanco Animal Health by 61.2% in the 2nd quarter. Magnetar Financial LLC now owns 8,336,657 shares of the company’s stock valued at $120,298,000 after purchasing an additional 3,164,350 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Elanco Animal Health by 363.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,548,506 shares of the company’s stock worth $22,748,000 after buying an additional 1,214,123 shares in the last quarter. Great Lakes Advisors LLC bought a new position in shares of Elanco Animal Health during the 2nd quarter worth approximately $16,043,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Elanco Animal Health by 4.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock valued at $360,425,000 after buying an additional 852,281 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ELAN. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $17.00 to $15.00 in a research note on Thursday, September 19th. Barclays upped their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and an average target price of $17.14.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN opened at $14.04 on Friday. The business has a fifty day moving average of $13.84 and a 200-day moving average of $14.75. The firm has a market cap of $6.94 billion, a PE ratio of 35.10, a price-to-earnings-growth ratio of 1.48 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health Incorporated has a twelve month low of $11.20 and a twelve month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the company posted $0.18 EPS. The company’s quarterly revenue was down 3.6% compared to the same quarter last year. On average, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Michael J. Harrington acquired 3,500 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was purchased at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the transaction, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. This trade represents a 4.51 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.